Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are indicated for the treatment of type 2 diabetes and may also improve glucose control in type 1 diabetes. In 2015, regulatory agencies warned that SGLT2i may favour diabetic ketoacidosis (DKA). We provide a detailed analysis of DKA reports in which an SGLT2i was listed among suspect or concomitant drugs in the US Food and Drug Administration Adverse Event Reporting System (FAERS).
SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System
FADINI, GIAN PAOLO;BONORA, BENEDETTA MARIA;AVOGARO, ANGELO
2017
Abstract
Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are indicated for the treatment of type 2 diabetes and may also improve glucose control in type 1 diabetes. In 2015, regulatory agencies warned that SGLT2i may favour diabetic ketoacidosis (DKA). We provide a detailed analysis of DKA reports in which an SGLT2i was listed among suspect or concomitant drugs in the US Food and Drug Administration Adverse Event Reporting System (FAERS).
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
art%253A10.1007%252Fs00125-017-4301-8.pdf
accesso aperto
Descrizione: PDF
Tipologia:
Published (Publisher's Version of Record)
Licenza:
Altro
Dimensione
640.29 kB
Formato
Adobe PDF
|
640.29 kB | Adobe PDF | Visualizza/Apri |
|
125_2017_4301_MOESM1_ESM.pdf
accesso aperto
Descrizione: Suppl materials
Tipologia:
Altro materiale allegato
Licenza:
Altro
Dimensione
37.38 kB
Formato
Adobe PDF
|
37.38 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
